| Background | HY-P990946 is an CLDN18-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• Claudin 18.2 as a novel therapeutic target., PMID:38503878
• Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?, PMID:38339430
• Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach., PMID:39098518
• Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial., PMID:37524953
• Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development., PMID:19047087
• Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer., PMID:36610262
• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial., PMID:37068504
• Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression., PMID:38200591
• Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., PMID:37860278
• Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer., PMID:28494772
|
|---|
